Mercy M. MbaiEmmanuel MdumaSamuel ThuoEulade RugengamanziChristina V. MalicheweEmmanuel L. Lugina2025-02-212025-02-212024-07-03https://doi.org/10.1186/s12885-024-12569-zhttps://dspace.ughe.org/handle/123456789/238<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>The incidence of Hodgkin's lymphoma (HL) in people living with HIV (PLWHA) and on HAART is approximately 20–30 times higher than in HIV-negative individuals. Most patients with HIV-HL present at an advanced stage (III-IV) have 'B' symptoms and extranodal involvement. The natural history and risk stratification of HIV-HL has undergone a significant change as a result of HAART's rollout. This study investigated the differences in clinicopathological and survival patterns of HL among individuals with and without HIV disease in Tanzania during the HAART era.</jats:p> </jats:sec><jats:sec> <jats:title>Methodology</jats:title> <jats:p>This hospital-based retrospective cohort study was conducted at the ORCI, Dar-Es-Salaam, Tanzania. Chi-square and Fisher’s exact tests were used to compare proportions. The student t-test was used to compare means. To determine factors that predict survival, we used the log-rank test to analyze the variables in univariate analysis. A Cox regression model was used to analyze the significant factors from univariate analysis in multivariate analysis.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Eighty-three patients with HL were recruited, and the prevalence of HIV-positive status was 27.7%. Most of the patients with HIV-HL had an age of &gt; 30 years (73.9%), while most of the non-HIV-HL patients had an age of ≤ 30 years (63.3%) (<jats:italic>P</jats:italic> = 0.02). The 2-year OS rate for HIV-HL was 34%, while that for non-HIV-HL was 67%. Among the HIV-HL patients, predictors of a poorer outcome were a CD4 count ≤ 200 cells/mm3 (<jats:italic>P</jats:italic> = 0.05), lack of HAART use (<jats:italic>P</jats:italic> = 0.00), and the use of HAART for ≤ 10 months (<jats:italic>P</jats:italic> = 0.00).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The prevalence of HIV-HL was 27.7% among HL patients. HIV positivity is still a poor prognostic factor in our setting, especially for patients not on HAART, on HAART for ≤ 10 months, or with a low CD4 count below 200 cells/mm3. Patients with HIV-HL were older and had higher LDH levels, whereas patients with non-HIV-HL were younger and had low LDH levels.</jats:p> </jats:sec>enHIVHodgkin's LymphomaTanzaniajournal-article